, de Médecine Interne et Immunologie Clinique, F-59000 Lille, France. 4 Centre National de Référence Maladies Systémiques et Auto-immunes Rares
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 ,
, Service d'Explorations Fonctionnelles Respiratoires, F-59000
Diagnosis and classification of systemic sclerosis, Clin Rev Allergy Immunol, vol.40, pp.78-83, 2011. ,
Changes in causes of death in systemic sclerosis, Ann Rheum Dis, vol.66, pp.940-944, 1972. ,
Six-minute walk test in systemic sclerosis: a systematic review and meta-analysis, Int J Cardiol, vol.212, pp.265-73, 2016. ,
A simple field test for the assessment of physical fitness, Rep Civ Aeromed Res Inst US, vol.6, pp.1-8, 1963. ,
Technical Standard: field walking tests in chronic respiratory disease, Eur Respir J, vol.44, pp.1428-1474, 2014. ,
Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing, Am J Respir Crit Care Med, vol.161, pp.487-92, 2000. ,
Sixminute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, vol.174, pp.659-64, 2006. ,
The 6-min walking distance: long-term follow up in patients with COPD, Eur Respir J, vol.29, pp.535-575, 2007. ,
The 6-minute walk test in scleroderma-how measuring everything measures nothing, Rheumatol Oxf Engl, vol.47, issue.5, pp.68-77, 2008. ,
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial, Ann Intern Med, vol.132, pp.425-459, 2000. ,
Bosentan therapy for pulmonary arterial hypertension, N Engl J Med, vol.346, pp.896-903, 2002. ,
Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease, Chest, vol.126, pp.420-427, 2004. ,
Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease, Eur J Clin Invest, vol.36, issue.3, pp.44-52, 2006. ,
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis, Arthritis Rheum, vol.62, pp.2101-2109, 2010. ,
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test, Ann Rheum Dis, vol.66, pp.169-73, 2007. ,
Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients, Chest, vol.131, pp.217-239, 2007. ,
Assessment of left and right ventricular diastolic function in patients with systemic sclerosis, Kardiol Pol, vol.66, pp.277-285, 2008. ,
Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma, J Rheumatol, vol.36, pp.330-336, 2009. ,
Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis, J Rheumatol, vol.36, pp.1481-1486, 2009. ,
Relationship between left ventricular diastolic dysfunction and six minute walk test in patients with systemic sclerosis, Int J Rheum Dis, vol.14, pp.379-83, 2011. ,
Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis, Clin Exp Rheumatol, vol.29, pp.53-62, 2011. ,
The sixminute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease, Respirology, vol.17, pp.647-52, 2012. ,
Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, Arthritis Care Res, vol.65, pp.454-63, 2013. ,
Six-minute walk test reflects neurohormonal activation and right ventricular function in systemic sclerosis patients, Clin Exp Rheumatol, vol.31, pp.18-23, 2013. ,
Relationship between functional capacity, joint mobility and pulmonary function in patients with systemic sclerosis, J Bodyw Mov Ther, vol.19, pp.17-24, 2015. ,
Lower limb muscle strength is associated with functional performance and quality of life in patients with systemic sclerosis, Braz J Phys Ther, vol.19, pp.129-165, 2015. ,
Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease, Clin Exp Rheumatol, vol.33, pp.142-149, 2015. ,
An explanatory model of functional exercise capacity in patients with systemic sclerosis: considerations for rehabilitation programs, J Phys Ther Sci, vol.28, pp.569-75, 2016. ,
Echocardiographic Predictors for Worsening of Six-Minute Walk Distances in Patients With Systemic Sclerosis (Scleroderma), Am J Cardiol, vol.120, pp.315-336, 2017. ,
Six-minute walk test in or out in evaluation of systemic sclerosis patients?, Clin Exp Rheumatol, vol.35, issue.4, pp.122-129, 2017. ,
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, vol.72, pp.1747-55, 2013. ,
, ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test, Am J Respir Crit Care Med, vol.166, pp.111-118, 2002.
Reference equations for the six-minute walk in healthy adults, Am J Respir Crit Care Med, vol.158, pp.1384-1391, 1998. ,
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes, Ann Rheum Dis, vol.60, pp.592-600, 2001. ,
Assessment of disease severity and prognosis in systemic sclerosis, Clin Exp Rheumatol, vol.21, pp.42-48, 2003. ,
Measurement of patient outcome in arthritis, Arthritis Rheum, vol.23, pp.137-182, 1980. ,
R: A language and environment for statistical computing, 2008. ,
Impaired chronotropic response to 6-min walk test and reduced survival in interstitial lung disease, Respir Med, vol.107, pp.1066-72, 2013. ,
Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension, Eur Respir J, vol.27, pp.114-134, 2006. ,
Heart rate response in stress testing: clinical implications, ACC Curr J Rev, vol.10, pp.16-25, 2001. ,
Chronotropic incompetence: causes, consequences, and management, Circulation, vol.123, pp.1010-1030, 2011. ,
Neurologic involvement in scleroderma: a systematic review, Semin Arthritis Rheum, vol.43, pp.335-382, 2013. ,
Heart rate turbulence assessment in systemic sclerosis: the role for the detection of cardiac autonomic nervous system dysfunction, Rheumatol Oxf Engl, vol.49, pp.355-60, 2010. ,
Factors relating to impaired stroke volume during the 6-minute walk test in patients with systemic sclerosis, Clin Exp Rheumatol, vol.34, pp.152-158, 2016. ,
Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease, Eur J Heart Fail, vol.8, pp.321-326, 2006. ,
Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis, Respir Med, vol.106, pp.1613-1634, 2012. ,
Short term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis: pulmonary function trends in SSc-ILD, Arthritis Rheumatol. Arthritis Rheumatol, vol.69, issue.8, pp.1670-1678, 2017. ,
Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease, PLoS One, vol.12, p.181692, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02519638
A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension, Ann Rheum Dis, vol.75, pp.1457-65, 2016. ,
Lack of correlation of the health assessment questionnaire disability index with lung parameters in systemic sclerosis associated pulmonary arterial hypertension, Clin Exp Rheumatol, vol.26, pp.1012-1019, 2008. ,
Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort, Respir Med, vol.104, pp.849-57, 2010. ,
Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group, Arthritis Care Res, vol.64, pp.1405-1419, 2012. ,
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis, Arthritis Rheum, vol.42, pp.2372-80, 1999. ,